Ermanno Rondini

673 total citations
32 papers, 394 citations indexed

About

Ermanno Rondini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ermanno Rondini has authored 32 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Ermanno Rondini's work include Cancer Treatment and Pharmacology (6 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Breast Cancer Treatment Studies (5 papers). Ermanno Rondini is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Breast Cancer Treatment Studies (5 papers). Ermanno Rondini collaborates with scholars based in Italy, United States and Canada. Ermanno Rondini's co-authors include Fabrizio Artioli, Francesco Cardini, Laura Scaltriti, Paolo Pandolfi, Roberto Sabbatini, Elisa Stivanello, Pamela Mancuso, Rodolfo Passalacqua, Muriel Assunta Musti and Giorgia Razzini and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Ermanno Rondini

30 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ermanno Rondini Italy	10	178	137	127	74	65	32	394
Yunte Deng China	8	142 0.8×	75 0.5×	65 0.5×	25 0.3×	114 1.8×	9	389
Giovanni Iodice Italy	9	273 1.5×	141 1.0×	135 1.1×	48 0.6×	49 0.8×	19	499
Marianne Melnik United States	11	158 0.9×	45 0.3×	96 0.8×	25 0.3×	18 0.3×	17	273
Weifeng Wang China	8	154 0.9×	34 0.2×	45 0.4×	54 0.7×	56 0.9×	30	337
Katie Wang Canada	8	118 0.7×	63 0.5×	54 0.4×	55 0.7×	78 1.2×	11	356
Yin Zongyi China	7	145 0.8×	77 0.6×	108 0.9×	59 0.8×	129 2.0×	14	443
Paola Sgandurra Italy	10	226 1.3×	118 0.9×	63 0.5×	93 1.3×	61 0.9×	13	488
Jean‐Pierre Bleuse France	11	309 1.7×	125 0.9×	63 0.5×	38 0.5×	84 1.3×	21	468
Lise Eckhoff Denmark	11	548 3.1×	27 0.2×	94 0.7×	63 0.9×	59 0.9×	15	687
Alexandra Desnoyers Canada	10	156 0.9×	55 0.4×	99 0.8×	41 0.6×	62 1.0×	32	318

Countries citing papers authored by Ermanno Rondini

Since Specialization

Citations

This map shows the geographic impact of Ermanno Rondini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ermanno Rondini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ermanno Rondini more than expected).

Fields of papers citing papers by Ermanno Rondini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ermanno Rondini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ermanno Rondini. The network helps show where Ermanno Rondini may publish in the future.

Co-authorship network of co-authors of Ermanno Rondini

This figure shows the co-authorship network connecting the top 25 collaborators of Ermanno Rondini. A scholar is included among the top collaborators of Ermanno Rondini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ermanno Rondini. Ermanno Rondini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghirotto, Luca, Euǵenio Paci, Valentina Bessi, et al.. (2025). Self-blaming as a barrier to lung cancer screening and smoking cessation programs in Italy. A qualitative study. PLoS ONE. 20(3). e0318732–e0318732.

Mazzini, Elisa, et al.. (2023). Activities Carried Out during the First COVID-19 Lockdown by Italian Citizens. International Journal of Environmental Research and Public Health. 20(5). 3906–3906. 1 indexed citations

Costi, Stefania, Elisa Mazzini, Silvio Cavuto, et al.. (2021). Beyond Lockdown: The Potential Side Effects of the SARS-CoV-2 Pandemic on Public Health. Nutrients. 13(5). 1600–1600. 23 indexed citations

Damato, Angela, et al.. (2021). Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report. Frontiers in Oncology. 11. 670415–670415. 1 indexed citations

Damato, Angela, et al.. (2017). Severe Rhabdomyolysis during Treatment with Trabectedin in Combination with a Herbal Drug in a Patient with Metastatic Synovial Sarcoma: A Case Report. Case Reports in Oncology. 10(1). 258–264. 7 indexed citations

Passalacqua, Rodolfo, Silvia Lazzarelli, Maddalena Donini, et al.. (2017). Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014). BMC Cancer. 17(1). 493–493. 4 indexed citations

Passalacqua, Rodolfo, Silvia Lazzarelli, Rodolfo Montironi, et al.. (2016). Vinflunine (VFL) in patients (pts) with metastatic transitional cell carcinoma of the urothelial tract (mTCCU): Clinical outcome and prognostic factors in a nationwide, real-life setting (MOVIE trial).. Journal of Clinical Oncology. 34(15_suppl). e16031–e16031. 4 indexed citations

Donini, Maddalena, Rodolfo Passalacqua, Rodolfo Montironi, et al.. (2015). Effectiveness and possible molecular factors predictive of clinical outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: a multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Annals of Oncology. 26. vi53–vi53. 1 indexed citations

Passalacqua, Rodolfo, Rodolfo Montironi, Silvia Lazzarelli, et al.. (2015). 2639 Effectiveness and possible Molecular factors predictive of clinical Outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: A multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). European Journal of Cancer. 51. S526–S527. 1 indexed citations

10.

Passalacqua, Rodolfo, Caterina Caminiti, Sebastiano Buti, et al.. (2014). Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC). Journal of Immunotherapy. 37(9). 440–447. 59 indexed citations

11.

Tinterri, Corrado, Wolfgang Gatzemeier, A. Costa, et al.. (2013). Breast-Conservative Surgery With and Without Radiotherapy in Patients Aged 55–75 Years With Early-Stage Breast Cancer: A Prospective, Randomized, Multicenter Trial Analysis After 108 Months of Median Follow-up. Annals of Surgical Oncology. 21(2). 408–415. 35 indexed citations

12.

Montanari, Marco, Francesco� Fabbri, Ermanno Rondini, et al.. (2012). Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer.. PubMed. 98(6). 696–701. 13 indexed citations

13.

Bajetta, Emilio, Irene Floriani, Maria Di Bartolomeo, et al.. (2012). Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.. Journal of Clinical Oncology. 30(18_suppl). LBA4001–LBA4001. 5 indexed citations

14.

Montanari, Marco, Francesco� Fabbri, Giovanni Luca Frassineti, et al.. (2010). Phase II trial of nonpegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: A translational study.. Journal of Clinical Oncology. 28(15_suppl). 4683–4683. 3 indexed citations

15.

Tinterri, Corrado, Wolfgang Gatzemeier, V. Zanini, et al.. (2009). Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: A prospective randomised multicentre trial. The Breast. 18(6). 373–377. 46 indexed citations

16.

Cocconi, Giorgio, C. Boni, Giancarlo Bisagni, et al.. (2005). Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes. Annals of Oncology. 16(9). 1469–1476. 7 indexed citations

17.

Cocconi, Giorgio, C. Boni, Giancarlo Bisagni, et al.. (2002). Randomized trial comparing cyclophosphamide, methotrexate, and 5–fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cancer. 95(2). 228–235. 6 indexed citations

18.

Colozza, Mariantonietta, Giancarlo Bisagni, Anna Maria Mosconi, et al.. (2002). Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study. European Journal of Cancer. 38(17). 2279–2288. 11 indexed citations

19.

Boni, C., Luisa Savoldi, Giancarlo Bisagni, et al.. (1998). Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC). European Journal of Cancer. 34(12). 1974–1976. 2 indexed citations

20.

Bisagni, Giancarlo, C. Boni, Gabriella Moretti, et al.. (1998). Ifosfamide Bolus Followed by Five Days Continuous Infusion in Extensively Pretreated Patients with Advanced Breast Cancer: A Phase II Study. Tumori Journal. 84(6). 659–661. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact